 CELEBRATION, Fla., July 21, 2021 GLOBE NEWSWIRE -- KemPharm, Inc. NASDAQ: KMPH, a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYSTM, a once-daily product for the treatment of attention deficit hyperactivity disorder ADHD in patients age six years and older. Corium, Inc. Corium, a portfolio company of Gurnet Point Capital GPC, is leading the commercialization of AZSTARYS in the U.S. 